GSK Plc’s blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

The U.S. Food and Drug Administration's panel of independent advisers voted on Thursday against approval of GSK's blood ...

GSK (GSK) stock slips as FDA advisors vote against the approval of a combination regimen involving thecompany's blood cancer drug Blenrep. Read more here.

The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

GSK PLC closed 16.45% short of its 52-week high of £16.79, which the company reached on September 9th.

GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...